Adial Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview

Adial Pharmaceuticals

12/05/2023 12:23

* Adial Pharmaceuticals Inc  ADIL.OQ   ADIL.O  is expected
to show
no change in quarterly revenue when it reports  results on May
15 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Adial
Pharmaceuticals Inc
is for a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adial
Pharmaceuticals Inc is $6​, above​ its last closing price
of $0.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.19       -0.18      -0.12     Beat    33.3
 Jun. 30 2022  -0.12       -0.14      -0.16     Missed  -10.3
 Mar. 31 2022  -0.17       -0.17      -0.13     Beat    23.5​
 Dec. 31 2021  -0.20       -0.21      -0.28     Missed  -36
 ​​Sep.        -0.22       -0.22      -0.22     Met     0
 30 2021                                                
 Jun. 30 2021  -0.21       -0.20      -0.25     Missed  -22​
 Dec. 31 2020              -0.25      -0.24     Beat    4
 This summary was machine generated May 12 at 11:23 GMT.  All
figures in US dollars  unless otherwise stated